Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis.

ABSTRACT:

Aim

The objectives of this study were to characterize age-related changes in lamivudine pharmacokinetics in children and evaluate lamivudine exposure, followed by dose recommendations for subgroups in which target steady state area under the daily plasma concentration-time curve (AUC_0-24h ) is not reached.

Methods

Population pharmacokinetic modelling was performed in NONMEM using data from two model-building datasets and two external datasets [n = 180 (age 0.4-18 years, body weight 3.4-60.5 kg); 2061 samples (median 12 per child); daily oral dose 60-300 mg (3.9-17.6 mg kg^-1 )]. Steady state AUC_0-24h was calculated per individual (adult target 8.9 mg·h l^-1 ).

Results

A two-compartment model with sequential zero order and firs

SUBMITTER: Janssen EJH 

PROVIDER: S-EPMC5427247 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature